{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-018609","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.935694+00:00","generated_at":"2026-06-29T22:08:25.240712+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Techne Q4 FY2021 revenue up 47% to $259M; adjusted EPS $1.87 vs $1.00 YoY","bullets":["Q4 organic revenue rose 39% to $259.0M; GAAP EPS $0.37, adjusted EPS $1.87 (vs $1.00 prior year).","Full-year revenue $931.0M, adjusted EPS $6.75, record operating cash flow $352M.","Protein Sciences organic +46%, Diagnostics & Genomics +22%; adj. operating margin 38.5% vs 31.1%.","Board declares $0.32/share quarterly dividend, payable Aug 27, 2021 to holders of record Aug 16, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-018609","json":"https://secwatch.observer/filing/0001437749-21-018609.json","markdown":"https://secwatch.observer/filing/0001437749-21-018609.md","text":"https://secwatch.observer/filing/0001437749-21-018609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000143774921018609/0001437749-21-018609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000143774921018609/tech20210804_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:08:25.240712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}